Pyxis Oncology (NAS:PYXS) Other Operating Expense

: $-0.00 Mil (TTM As of Dec. 2022)

View and export this data going back to 2021. Start your Free Trial

Pyxis Oncology's Other Operating Expense for the three months ended in Dec. 2022 was $0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.00 Mil.

Pyxis Oncology's quarterly Other Operating Expense increased from Jun. 2022 ($-0.00 Mil) to Sep. 2022 ($0.00 Mil) but then declined from Sep. 2022 ($0.00 Mil) to Dec. 2022 ($0.00 Mil).

Pyxis Oncology's annual Other Operating Expense declined from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($-0.00 Mil) and declined from Dec. 2021 ($-0.00 Mil) to Dec. 2022 ($-0.00 Mil).

Pyxis Oncology Other Operating Expense Historical Data

The historical data trend for Pyxis Oncology's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pyxis Oncology Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Other Operating Expense

Pyxis Oncology Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Other Operating Expense								-	-	-	-	-

Pyxis Oncology Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

Pyxis Oncology Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Pyxis Oncology's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Pyxis Oncology (NAS:PYXS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pyxis Oncology Inc (NAS:PYXS) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

35 CambridgePark Drive, Cambridge, MA, USA, 02140

Website

https://www.pyxisoncology.com

Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.

Executives

Pfizer Inc	10 percent owner	235 E 42ND ST, NEW YORK NY 10017
Pfizer Ventures (us) Llc	10 percent owner	235 EAST 42ND STREET, NEW YORK NY 10017
Rachel Humphrey	director	C/O MIRATI THERAPEUTICS INC., 4660 LA JOLLA VILLAGE DRIVE, SUITE 500, SAN DIEGO CA 92121
Jitendra Wadhane	officer: SVP, Chief Accounting Officer	35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Plc Barclays	10 percent owner	1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
Mark Chin	other: Former Director	20 BERKELEY SQUARE, MAYFAIR, LONDON X0 W1J 6EQ
Darren S Cline	director	35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Yanchik Connealy Pamela	officer: Chief Financial Officer	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Thomas Civik	director	C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141
Bayer World Investments B.v.	10 percent owner	ENERGIEWEG 1, MIJDRECHT P7 3641
Freda C Lewis-hall	director	C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Ronald Herbst	officer: Chief Scientific Officer	35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Jay Feingold	officer: Chief Medical Officer	C/O PYXIS ONCOLOGY, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Ritu Shah	officer: Chief Operating Officer	35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
John L Flavin	director	C/O MEDICHEM LIFE SCIENCES INC, 12305 SOUTH NEW AVENUE, LEMONT IL 60439